脂質異常症（Hyperlipidemia）：グローバル臨床試験レビュー（2014年上半期）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hyperlipidemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hyperlipidemia to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hyperlipidemia to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Hyperlipidemia 25
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Hyperlipidemia Therapeutics Clinical Trials 31
Prominent Drugs 33
Latest Clinical Trials News on Hyperlipidemia 34
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen’s Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 34
Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia 36
Feb 26, 2013: Merck’s Niacin-Statin Combination Significantly Increases Adverse Side-effects, Phase III Study Shows 36
Jan 15, 2013: Mochida Pharma Announces Phase II Results Of Epadel For Treatment Of Hyperlipidemia And Arteriosclerosis Obliterans 37
Nov 05, 2012: Roche’s Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds 38
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Merck & Co., Inc. 42
Clinical Trial Overview of Merck & Co., Inc. 42
AstraZeneca PLC 44
Clinical Trial Overview of AstraZeneca PLC 44
Abbott Laboratories 46
Clinical Trial Overview of Abbott Laboratories 46
Amgen Inc. 47
Clinical Trial Overview of Amgen Inc. 47
Kowa Company, Ltd. 48
Clinical Trial Overview of Kowa Company, Ltd. 48
HanAll Biopharma Co., Ltd. 49
Clinical Trial Overview of HanAll Biopharma Co., Ltd. 49
Daiichi Sankyo Company, Limited 50
Clinical Trial Overview of Daiichi Sankyo Company, Limited 50
Hanmi Science Co., Ltd. 51
Clinical Trial Overview of Hanmi Science Co., Ltd. 51
Cipher Pharmaceuticals Inc. 52
Clinical Trial Overview of Cipher Pharmaceuticals Inc. 52
Clinical Trial Overview of Top Institutes / Government 53
University of Toronto 53
Clinical Trial Overview of University of Toronto 53
National Heart, Lung, and Blood Institute 54
Clinical Trial Overview of National Heart, Lung, and Blood Institute 54
Central South University 55
Clinical Trial Overview of Central South University 55
University of Manitoba 56
Clinical Trial Overview of University of Manitoba 56
U.S. Department of Veterans Affairs 57
Clinical Trial Overview of U.S. Department of Veterans Affairs 57
Stanford University 58
Clinical Trial Overview of Stanford University 58
Emory University 59
Clinical Trial Overview of Emory University 59
The Ohio State University 60
Clinical Trial Overview of The Ohio State University 60
University of Colorado 61
Clinical Trial Overview of University of Colorado 61
Hiroshima University Hospital 62
Clinical Trial Overview of Hiroshima University Hospital 62
Five Key Clinical Profiles 63
Appendix 118
Abbreviations 118
Definitions 118
Research Methodology 119
Secondary Research 119
About GlobalData 120
Contact Us 120
Disclaimer 120
Source 120